# DREAMM-10: HCP commentary report

> 349 verified statements (284 from speakers with a confirmed clinical role) from 41 commentary sources · 8 findings · updated Oct 25, 2026

## Report

- Trial: A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- NCT ID: NCT06679101
- Registry: https://clinicaltrials.gov/study/NCT06679101
- Sponsor: GlaxoSmithKline
- Phase: Phase 3
- Status: Recruiting
- Drugs: lenalidomide, dexamethasone, daratumumab
- Indications: Multiple myeloma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-25
- Last checked: 2026-10-25
- Release hash: 9984acebd41e416bc77ceaa5fc548e3353a46378d7866711ea0f567b4a14d4f0

## Counts

- HCP commentary sources screened: 166
- Sources cited by verified statements: 41
- Verified statements: 349
- From speakers with a confirmed clinical role: 284
- Findings: 8
- People found in screened sources: 32
- People identity-verified: 25
- Voices cited: 31

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

DREAMM-10 asks whether belantamab can replace daratumumab alongside lenalidomide and dexamethasone for newly diagnosed multiple myeloma in patients ineligible for transplantation. Clinicians in the sources reviewed for this edition disagree about a frontline role, with some views conditional on access. They express enthusiasm about efficacy expectations while scrutinizing dose spacing and ocular burden. Comparative benefit and the choice between replacement and combination remain unresolved.

## Open Medical Affairs question

For which transplant-ineligible patients would an access advantage justify the ocular-monitoring and functional burden compared with DRd or a CD38-containing quadruplet?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A frontline role is disputed and, for some clinicians, explicitly access-dependent
- F2. Replacing daratumumab is a different question from adding belantamab
- F3. Dose spacing is viewed as an efficacy–tolerability window, not simply less treatment
- F4. Strong efficacy expectations remain extrapolations, not DREAMM-10 findings
- F5. Ocular recovery and response during holds do not eliminate patient burden
- F6. Questionnaire-led monitoring is a research prospect, not an established replacement for eye examinations
- F7. Duration, risk and frailty complicate a simple escalation narrative
- F8. Preservation of later BCMA options is an explicitly tentative rationale

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 14 | 11 | 6 | 7 | recorded | 3 |
| F2 | 29 | 24 | 7 | 9 | recorded | 3 |
| F3 | 21 | 19 | 14 | 13 | recorded | 4 |
| F4 | 29 | 19 | 10 | 8 | recorded | 4 |
| F5 | 36 | 23 | 8 | 8 | recorded | 4 |
| F6 | 24 | 17 | 6 | 7 | recorded | 3 |
| F7 | 30 | 20 | 6 | 7 | recorded | 5 |
| F8 | 5 | 3 | 3 | 3 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 9 | 2 | 1 | 1 | 1 | 14 | 4 | 4 posts and articles, 2 podcasts and video | yes |
| F2 | 14 | 5 | 2 | 4 | 4 | 34 | 18 | 1 post or article, 6 podcasts and video | yes |
| F3 | 9 | 5 | 0 | 5 | 2 | 25 | 4 | 7 posts and articles, 7 podcasts and video | yes |
| F4 | 3 | 9 | 0 | 3 | 14 | 31 | 13 | 1 post or article, 9 podcasts and video | yes |
| F5 | 9 | 8 | 10 | 4 | 5 | 41 | 15 | 1 post or article, 7 podcasts and video | yes |
| F6 | 3 | 3 | 4 | 1 | 13 | 26 | 12 | 2 posts and articles, 4 podcasts and video | yes |
| F7 | 16 | 4 | 3 | 1 | 6 | 38 | 6 | 1 post or article, 5 podcasts and video | yes |
| F8 | 3 | 0 | 1 | 1 | 0 | 5 | 0 | 3 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: PFS: F4 (5 shared claims)
- Primary endpoint: Number of Participants Achieving MRD Negative Status: F4 (7 shared claims), F5 (1 shared claims), F7 (1 shared claims)
- Secondary endpoints: F4 (3 shared claims), F5 (6 shared claims), F7 (1 shared claims), F8 (1 shared claims)
- Population and setting: F1 (8 shared claims), F2 (2 shared claims), F4 (1 shared claims), F5 (1 shared claims), F7 (1 shared claims)
- The comparison: F2 (10 shared claims), F3 (1 shared claims), F4 (3 shared claims)
- Safety and tolerability: F3 (2 shared claims), F5 (15 shared claims), F6 (2 shared claims)
- Design and conduct: no finding draws on it directly

## Sample findings

Paraphrased; the full report links each statement to its source.

### F4. Strong efficacy expectations remain extrapolations, not DREAMM-10 findings

A speaker in a YouTube discussion asked whether belantamab-Rd could match or improve on daratumumab-Rd in DREAMM-10.

Source: YouTube video, 2026-01-02.

### F3. Dose spacing is viewed as an efficacy–tolerability window, not simply less treatment

A participant in an X thread asked how the starting belantamab dose was selected for DREAMM-10.

Source: X thread, 2026-04-18.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 349 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 41 | Counts free |
| Speaker attribution for cited voices | 31 | Paid |

## Trial aspects

13 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: PFS | discussed | 5 | 2 |
| Primary endpoint: Number of Participants Achieving MRD Negative Status | discussed | 9 | 6 |
| Secondary endpoints | discussed | 11 | 6 |
| Population and setting | discussed | 13 | 8 |
| The comparison | discussed | 14 | 7 |
| Safety and tolerability | discussed | 19 | 9 |
| Design and conduct | no commentary found | 0 | 0 |
| Starting exposure, dosing intervals and induction–maintenance trade-offs | discussed | 21 | 14 |
| Eye-care access, monitoring research and treatment coordination | discussed | 24 | 6 |
| Addition versus replacement and the evolving frontline alternatives | discussed | 17 | 6 |
| Treatment duration, sustained MRD and the shared Rd backbone | discussed | 27 | 6 |
| Consequences of initial treatment for later BCMA and CD38 options | discussed | 5 | 3 |
| Community reach, access-dependent selection and patient support | discussed | 17 | 7 |
| Supporting-study comparability and changing comparator expectations | discussed | 26 | 10 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 123 | 25 |
| YouTube | 24 | 10 |
| Podcasts | 11 | 5 |
| Bluesky threads | 6 | 1 |
| X videos | 2 | 0 |

- Screened window: 2020-05-20 to 2026-10-19
- Cited window: 2024-02-07 to 2026-10-17
- Retrieved: 2026-10-24

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Registry: NCT06679101 (https://clinicaltrials.gov/study/NCT06679101)
- Study IDs: 214828 · 2024-516030-35 (CTIS)
- Sponsor: GlaxoSmithKline
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 520 (estimated)
- Start: 2024-12-16 (actual)
- Primary completion: 2031-04-28 (estimated)
- Primary endpoint: PFS (Up to approximately 7 years)
- Primary endpoint: Number of Participants Achieving MRD Negative Status (Up to approximately 7 years)
- Intervention: Belantamab mafodotin (drug)
- Intervention: Lenalidomide (drug)
- Intervention: Dexamethasone (drug)
- Intervention: Daratumumab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- Out of scope: 57 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
- 556 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not a representative survey of HCP opinion. Repeated statements and reposts do not establish independent agreement.
- No publication reporting DREAMM-10 outcomes was identified, and a full trial protocol was not available. Supporting-study findings and prospective expectations cannot be read as target-trial results.
- Some potentially relevant discussion of sequencing, community uptake, financial burden and comparative efficacy was not fully assessed. The report may therefore omit consequential qualifications or additional views.
- Coverage based on trial names and related terminology may miss unnamed references or alternative transcriptions.
- Some recorded passages were available only in their original transcript, leaving uncertainty about exact wording or speaker identification. Unidentified speakers remain unnamed.
- Regulatory documents were not comprehensively assessed. Monitoring and access statements reflect their source, date and jurisdiction, not a verified current standard everywhere.
- Small dose cohorts, differing follow-up, different regimens and inconsistent MRD or ocular-assessment denominators limit comparisons across the supporting studies.
- Some speakers described different DREAMM-10 dosing intervals. The reviewed material does not resolve those differences.
- Transplant-ineligible, transplant-deferred and quad-eligible populations are not interchangeable; related quadruplet discussions do not establish the same benefit–risk balance for all DREAMM-10 patients.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-25: current edition

Last checked for new commentary 2026-10-25. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Deep (349 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (25 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/dreamm-10-nct06679101
- Agents: POST https://www.erudio.com/api/orders with {"report": "dreamm-10-nct06679101", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=dreamm-10-06679101

## Cite

Erudio Health. DREAMM-10 (NCT06679101): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 25, 2026. https://www.erudio.com/reports/dreamm-10-nct06679101

## Machine access

- JSON: https://www.erudio.com/reports/dreamm-10-nct06679101.json
- Markdown: https://www.erudio.com/reports/dreamm-10-nct06679101.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "dreamm-10-06679101"}`